Abstract
Background Changes in the prevalence of mental health problems among smokers due to the COVID-19 pandemic in England have important implications for existing health inequalities. This study examined the prevalence of psychological distress among smokers following the onset of the pandemic compared with previous years.
Methods Cross-sectional data were used from a representative survey of smokers (18+) in England (n = 2,927) during four months (April to July) in 2016, 2017 and 2020. Adjusted logistic regressions estimated the associations between past-month psychological distress across two time periods (2016/17 and 2020), and age. Weighted proportions, chi-squared statistics and stratified logistic regression models were used to compare the distributions of minimal, moderate and severe distress, respectively, within socio-demographic and smoking characteristic categories in 2016/17 and 2020.
Results The prevalence of moderate and severe distress among past-year smokers was higher in 2020 (moderate: 28.79%, 95%CI 26.11-31.60; OR=2.08, 95%CI 1.34-3.25; severe: 11.04%, 9.30-13.12; OR=2.16, 1.13-4.07) than in 2016/17 (moderate: 20.66%, 19.02-22.43; severe: 8.23%, 7.16-9.47). While there was no overall evidence of an interaction between time period and age, young (16-24 years) and middle-age groups (45-54 years) may have experienced greater increases in moderate and older age groups (65+ years) in severe distress from 2016/17 to 2020. There were also increases in 2020 of moderate distress among those from more disadvantaged social grades and of both moderate and severe distress among women and those with low cigarette addiction.
Conclusions Between April-July 2016/17 and April-July 2020 in England there were increases in both moderate and severe distress among smokers. The distribution of distress differed between 2016/17 and 2020 and represents a widening of established inequalities, with increases in distress among socio-economically disadvantaged groups, women and diverging age groups.
What this paper adds
Surveys in the UK indicate that there has been a deterioration in mental health of the general population since the onset of the COVID-19 pandemic.
Smoking is strongly associated with poor mental health, and a deterioration in mental health among smokers has potentially damaging consequences for existing health inequalities in the UK.
Our findings using data from a large population-based sample of adults in England show that between 2016/17 and 2020 there were increases in moderate and severe psychological distress among smokers.
Competing Interest Statement
Authors are members of the UK Prevention Research Partnership, an initiative funded by UK Research and Innovation Councils, the Department of Health and Social Care (England), and the UK devolved administrations and leading health research charities. JB reports receiving grants from Cancer Research UK during the conduct of the study and receiving unrestricted research funding from pharmaceutical companies who manufacture smoking cessation medications to study smoking cessation outside the submitted work. LS reports receiving honoraria for talks, receiving an unrestricted research grant and travel expenses to attend meetings and workshops by pharmaceutical companies that make smoking cessation products (Pfizer and Johnson & Johnson), and acting as a paid reviewer for grant-awarding bodies and as a paid consultant for health care companies. LK, LB, GM and MH have no competing interests to declare.
Funding Statement
We are grateful to Cancer Research UK and the UK Prevention Research Partnership for funding the study. Authors are members of the UK Prevention Research Partnership, an initiative funded by UK Research and Innovation Councils, the Department of Health and Social Care (England), and the UK devolved administrations and leading health research charities.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the STS is granted by the UCL Ethics Committee (ID 0498/001; ID: 2808/005). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline were used in the design and reporting of this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Pre-registered analysis plan and statistical code are available at https://osf.io/eh6sk/
